Chondroitin Sulfate Safety and Quality
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Mechanistic Target of Rapamycin Regulates the Oligodendrocyte Cytoskeleton During Myelination
Research ReportDevelopment/Plasticity/Repair Mechanistic Target of Rapamycin Regulates the Oligodendrocyte Cytoskeleton during Myelination https://doi.org/10.1523/JNEUROSCI.1434-18.2020 Cite as: J. Neurosci 2020; 10.1523/JNEUROSCI.1434-18.2020 Received: 31 May 2018 Revised: 23 February 2020 Accepted: 26 February 2020 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2020 Musah et al. 1 Mechanistic Target of Rapamycin Regulates the Oligodendrocyte Cytoskeleton during 2 Myelination 3 1Aminat S. Musah, 2Tanya L. Brown, 1Marisa A. Jeffries, 1Quan Shang, 2Hirokazu Hashimoto, 4 1Angelina V. Evangelou, 3Alison Kowalski, 3Mona Batish, 2Wendy B. Macklin and 1Teresa L. 5 Wood 6 1Department of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, 7 Rutgers University, Newark, NJ U.S.A. 07101, 2Department of Cell and Developmental Biology, 8 University of Colorado School of Medicine, Aurora, CO, U.S.A. 80045, 3Department of Medical 9 and Molecular Sciences, University of Delaware, Newark, DE 19716 10 11 Abbreviated Title: mTOR Regulates the Oligodendrocyte Cytoskeleton 12 Corresponding Author: Teresa L. Wood, PhD, Department Pharmacology, Physiology & 13 Neuroscience, New Jersey Medical School Cancer Center H1200, Rutgers University, 205 S. 14 Orange Ave, Newark, NJ 07101-1709 15 [email protected] 16 Number of pages: 39 17 Number of Figures: 10 18 Number of Tables: 0 19 Number of Words: 20 Abstract: 242 21 Introduction: 687 22 Discussion: 1075 23 Conflict of Interest: The authors declare no competing financial interests. -
Orthopaedic Bioengineering Research Laboratory 2010-2011
2010-2011 Report including the Orthopaedic Bioengineering Research Laboratory Preface It is my pleasure to present our 2010-2011 report been possible without a number of our donors from the Orthopaedic Research Center and the stepping up to provide supplemental funding. Orthopaedic Bioengineering Research Laboratory I’m particularly grateful to Mr. Jim Kennedy for at Colorado State University. Our principal focus providing supplemental operating funds and continues to be solving the significant problems in continuing the legacy of his mother, Barbara Cox equine musculoskeletal disease as can be seen in this Anthony. I’m also grateful to Abigail Kawananakoa report but we also continue to investigate questions for continued support over and above the Endowed relevant to human joint disease and techniques Chair she donated three years ago; and Herbert Allen and devices for human osteoarthritis and articular for continuing to provide considerable support for cartilage repair when the technique can also benefit investigation of cutting edge therapies. the horse. There have been a number of notable projects in this regard. The studies, led by Dr. Dave We have added an Equine Sports Medicine Frisbie at the ORC in partnership with Dr. Alan Ambulatory clinical arm to the Orthopaedic Research Grodzinsky at MIT on an NIH Program Grant in Center and also initiated two residencies in Sports cartilage repair, have been completed and results Medicine and Rehabilitation. This follows on from are still be analyzed. We have three other ongoing the accreditation of a new specialty college, the NIH grants in partnership with collaborators. One is American College of Veterinary Sports Medicine and with Dr. -
Sialylated Keratan Sulfate Chains Are Ligands for Siglec-8 in Human Airways
Sialylated Keratan Sulfate Chains are Ligands for Siglec-8 in Human Airways by Ryan Porell A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland September 2018 © 2018 Ryan Porell All Rights Reserved ABSTRACT Airway inflammatory diseases are characterized by infiltration of immune cells, which are tightly regulated to limit inflammatory damage. Most members of the Siglec family of sialoglycan binding proteins are expressed on the surfaces of immune cells and are immune inhibitory when they bind their sialoglycan ligands. When Siglec-8 on activated eosinophils and mast cells binds to its sialoglycan ligands, apoptosis or inhibition of mediator release is induced. We identified human airway Siglec-8 ligands as sialylated and 6’-sulfated keratan sulfate (KS) chains carried on large proteoglycans. Siglec-8- binding proteoglycans from human airways increase eosinophil apoptosis in vitro. Given the structural complexity of intact proteoglycans, target KS chains were isolated from airway tissue and lavage. Biological samples were extensively proteolyzed, the remaining sulfated glycan chains captured and resolved by anion exchange chromatography, methanol-precipitated then chondroitin and heparan sulfates enzymatically hydrolyzed. The resulting preparation consisted of KS chains attached to a single amino acid or a short peptide. Purified KS chains were hydrolyzed with either hydrochloric acid or trifluoroacetic acid to release acidic and neutral sugars, respectively, followed by DIONEX carbohydrate analysis. To isolate Siglec-8-binding KS chains, purified KS chains from biological samples were biotinylated at the amino acid, resolved by affinity and/or size- exclusion chromatography, the resulting fractions immobilized on streptavidin microwell plates, and probed for binding of Siglec-8-Fc. -
Compound Isolated from the Cock's Comb and Its Effect on Palmar Arsenical Keratosis
| Clinical | Trial | Compound isolated from the cock’s comb and its effect on palmar arsenical keratosis Hazera Sharmin and Mir Misbahuddin Article Info Abstract Division of Arsenic Research, This study was conducted to confirm the effectiveness of the ointment containing cock’s comb Department of Pharmacology, Faculty of extract and to identify the compound that was effective in the treatment of palmar arsenical Basic Science and Paraclinical Science, Bangabandhu Sheikh Mujib Medical keratosis. On the basis of inclusion and exclusion criteria, 24 patients with moderate to severe University, Shahbag, Dhaka, Bangladesh palmar arsenical keratosis were enrolled from an arsenic endemic area. The ointment prepared from the cock’s comb extract was supplied to each patient at an interval of 2 weeks. Each patient For Correspondence: was advised to apply the ointment on the nodule by rubbing gently up to 5 minutes and twice Mir Misbahuddin daily for 12 weeks. Improvement was monitored by measuring the nodular size before starting [email protected] and after completion of the treatment. The mean (± SD) size of the nodules of the palm before Received: 2 October 2019 treatment was 16.6 ± 5.0 mm2, which was reduced to 4.0 ± 3.8 mm2 after completion of the Accepted: 7 January 2020 treatment. This reduction was statistically significant. To identify the effective compound nuclear Available Online: 19 February 2020 magnetic resonance spectroscopy, infrared spectrophotometry, elemental analysis and liquid chromatography-mass spectroscopy of the extract were done yet conclusion could not be achieved. ISSN: 2224‐7750 (Online) 2074‐2908 (Print) DOI: 10.3329/bsmmuj.v13i1.45244 Introduction beneficial effect of the cock’s comb extract and Keywords: Arsenic; Cock‘s comb; to identify the compound that was effective in Keratosis; Palm Arsenical keratosis is not only a health problem the treatment of palmar arsenical keratosis. -
Acid Sustained Release Tablets with Water-Insoluble Gel
'1. j Available online at www.sciencedirect.com -.._ ~. - SCll!NCl!@DIRl!CT• 1 : Ü. Kiitüphane v;;ö 1 k ILFARMACO ELSEVIER ;' No M'-ttt-15. .. II Farmaco 58 (2003) 397 - 401 www.elsevier.com/locate/farmac • . ... ····· ····· ..... acid sustained release tablets with water-insoluble gel S. Güngör *, A. Y. Özsoy, E. Cevher, A. Araman Faculty of Pharmacy, Department of Pharmaceutical Technology, /stanbul Istanbul, Turkey Received 24 April 2002; accepted 28 November 2002 Abstract Mefenamic acid (MA) has analgesic, anti-inflammatory and antipyretic properties. Available conventional dosage forms are capsules and film-coated tablets. No commercial sustained release preparation of MA exists in the market. The usual oral dose is 250 or 500 mg and reported half-life is 2 h. Sodium alginate (NaAL) is the sodium salt of alginic acid, a natura! polysaccharide extracted from marine brown algae. it has the ability to forma water-insoluble gel with a bivalent metal ions as calcium. Therefore, NaAL has been studied for preparing sustained release formulations in pharmaceutical technology. In this study, tablet formulations containing different ratios of NaAL and calcium gluconate (CaGL) were prepared by direct compression method. In vitro release studies were carried out using USP 23 basket method and release data were kinetically evaluated. According to release studies, it can be emphasized that NaAL and CaGL can be used for design of sustained release preparation of MA. © 2003 Editions scientifiques et medicales Elsevier SAS. Ali rights reserved. Mefenamic acid; Sodium alginate; Calcium g]uconate; Sustained release 1. Introduction dispersing agent and gelation agent (10]. NaAL has the ability of forming rapid viscous solutions and gels by its Mefenamic acid (MA), 2-((2,3-dimethylphenyl)ami- contacts with aqueous media. -
Dietary Supplements for Osteoarthritis Philip J
Dietary Supplements for Osteoarthritis PHILIP J. GREGORY, PharmD; MORGAN SPERRY, PharmD; and AmY FRIEdmAN WILSON, PharmD Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska A large number of dietary supplements are promoted to patients with osteoarthritis and as many as one third of those patients have used a supplement to treat their condition. Glucosamine-containing supplements are among the most commonly used products for osteo- arthritis. Although the evidence is not entirely consistent, most research suggests that glucos- amine sulfate can improve symptoms of pain related to osteoarthritis, as well as slow disease progression in patients with osteoarthritis of the knee. Chondroitin sulfate also appears to reduce osteoarthritis symptoms and is often combined with glucosamine, but there is no reliable evi- dence that the combination is more effective than either agent alone. S-adenosylmethionine may reduce pain but high costs and product quality issues limit its use. Several other supplements are promoted for treating osteoarthritis, such as methylsulfonylmethane, Harpagophytum pro- cumbens (devil’s claw), Curcuma longa (turmeric), and Zingiber officinale (ginger), but there is insufficient reliable evidence regarding long-term safety or effectiveness. Am( Fam Physician. 2008;77(2):177-184. Copyright © 2008 American Academy of Family Physicians.) ietary supplements, commonly glycosaminoglycans, which are found in referred to as natural medicines, synovial fluid, ligaments, and other joint herbal medicines, or alternative structures. Exogenous glucosamine is derived medicines, account for nearly from marine exoskeletons or produced syn- D $20 billion in U.S. sales annually.1 These thetically. Exogenous glucosamine may have products have a unique regulatory status that anti-inflammatory effects and is thought to allows them to be marketed with little or no stimulate metabolism of chondrocytes.4 credible scientific research. -
Immunity to the G1 Globular Domain of the Cartilage Proteoglycan
Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo. J Y Leroux, … , S Banerjee, A R Poole J Clin Invest. 1996;97(3):621-632. https://doi.org/10.1172/JCI118458. Research Article Earlier work from this laboratory showed that the human proteoglycan aggrecan from fetal cartilages can induce a CD4+ T cell-dependent inflammatory polyarthritis in BALB/c mice when injected after removal of chondroitin sulfate chains. Adult keratan sulfate (KS)-rich aggrecan does not possess this property. We found that two CD4+ T cell hybridomas (TH5 and TH14) isolated from arthritic mice recognize bovine calf aggrecan and the purified G1 domain of this molecule, which also contains a portion of the interglobular domain to which KS is bound. These hybridoma responses to G1 are enhanced by partial removal of KS by the endoglycosidase keratanase or by cyanogen bromide cleavage of core protein. KS removal results in increased cellular uptake by antigen-present cells in vitro. After removal of KS by keratanase, G1 alone can induce a severe erosive polyarthritis and spondylitis in BALB/c mice identifying it as an arthritogenic domain of aggrecan. The presence of KS prevents induction of arthritis presumably as a result of an impaired immune response as observed in vitro. These observations not only identify the arthritogenic properties of G1 but they also point to the importance of glycosylation and proteolysis in determining the arthritogenicity of aggrecan and fragments thereof. -
Evaluation of Glucosamine Sulfate Compared to Ibuprofen for the Treatment of Temporomandibular Joint Osteoarthritis
Evaluation of Glucosamine Sulfate Compared to Ibuprofen for the Treatment of Temporomandibular Joint Osteoarthritis: A Randomized Double Blind Controlled 3 Month Clinical Trial NORMAN M.R. THIE, NARASIMHA G. PRASAD, and PAUL W. MAJOR ABSTRACT. Objective. To compare the treatment potential of glucosamine sulfate (GS) and ibuprofen in patients diagnosed with temporomandibular joint (TMJ) osteoarthritis (OA). Methods. Forty women and 5 men received either GS (500 mg tid) or ibuprofen (400 mg tid) for 90 days in a randomized double blind study. Assessment: TMJ pain with function, pain-free, and volun- tary maximum mouth opening, Brief Pain Inventory (BPI) questionnaire and masticatory muscle tenderness were performed after a one week washout and at Day 90. Acetaminophen (500 mg) dispensed for breakthrough pain was counted every 30 days to Day 120. Results. In total, 176 adults were interviewed, 45 (26%) qualified, 39 (87%) completed the study (21 GS, 18 ibuprofen). Four discontinued due to stomach upset (3 ibuprofen, one GS), one due to dizzi- ness (GS), one due to inadequate pain control (ibuprofen). Within-group analysis revealed signifi- cant improvement compared to baseline of all variables in both treatment groups but no change in acetaminophen used. Fifteen GS (71%) and 11 ibuprofen (61%) improved, with positive clinical response taken as a 20% decrease in primary outcome (TMJ pain with function). The number of patients with positive clinical response was not statistically different between groups (p = 0.73). Between-group comparison revealed that patients taking GS had a significantly greater decrease in TMJ pain with function, effect of pain, and acetaminophen used between Day 90 and 120 compared with patients taking ibuprofen. -
Modulation of Heparin Cofactor II Activity by Histidine-Rich Glycoprotein and Platelet Factor 4
Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4. D M Tollefsen, C A Pestka J Clin Invest. 1985;75(2):496-501. https://doi.org/10.1172/JCI111725. Research Article Heparin cofactor II is a plasma protein that inhibits thrombin rapidly in the presence of either heparin or dermatan sulfate. We have determined the effects of two glycosaminoglycan-binding proteins, i.e., histidine-rich glycoprotein and platelet factor 4, on these reactions. Inhibition of thrombin by heparin cofactor II and heparin was completely prevented by purified histidine-rich glycoprotein at the ratio of 13 micrograms histidine-rich glycoprotein/microgram heparin. In contrast, histidine-rich glycoprotein had no effect on inhibition of thrombin by heparin cofactor II and dermatan sulfate at ratios of less than or equal to 128 micrograms histidine-rich glycoprotein/microgram dermatan sulfate. Removal of 85-90% of the histidine-rich glycoprotein from plasma resulted in a fourfold reduction in the amount of heparin required to prolong the thrombin clotting time from 14 s to greater than 180 s but had no effect on the amount of dermatan sulfate required for similar anti-coagulant activity. In contrast to histidine-rich glycoprotein, purified platelet factor 4 prevented inhibition of thrombin by heparin cofactor II in the presence of either heparin or dermatan sulfate at the ratio of 2 micrograms platelet factor 4/micrograms glycosaminoglycan. Furthermore, the supernatant medium from platelets treated with arachidonic acid to cause secretion of platelet factor 4 prevented inhibition of thrombin by heparin cofactor II in the presence of heparin or dermatan sulfate. -
Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease
marine drugs Review Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease Muhammad Bilal 1,* , Leonardo Vieira Nunes 2 , Marco Thúlio Saviatto Duarte 3 , Luiz Fernando Romanholo Ferreira 4,5 , Renato Nery Soriano 6 and Hafiz M. N. Iqbal 7,* 1 School of Life Science and Food Engineering, Huaiyin Institute of Technology, Huaian 223003, China 2 Department of Medicine, Federal University of Juiz de Fora, Juiz de Fora-MG 36036-900, Brazil; [email protected] 3 Department of Medicine, Federal University of Juiz de Fora, Governador Valadares-MG 35010-180, Brazil; [email protected] 4 Graduate Program in Process Engineering, Tiradentes University (UNIT), Av. Murilo Dantas, 300, Farolândia, Aracaju-Sergipe 49032-490, Brazil; [email protected] 5 Institute of Technology and Research (ITP), Tiradentes University (UNIT), Av. Murilo Dantas, 300, Farolândia, Aracaju-Sergipe 49032-490, Brazil 6 Division of Physiology and Biophysics, Department of Basic Life Sciences, Federal University of Juiz de Fora, Governador Valadares-MG 35010-180, Brazil; [email protected] 7 School of Engineering and Sciences, Tecnologico de Monterrey, Monterrey 64849, Mexico * Correspondence: [email protected] or [email protected] (M.B.); hafi[email protected] (H.M.N.I.) Abstract: Naturally occurring biological entities with extractable and tunable structural and func- tional characteristics, along with therapeutic attributes, are of supreme interest for strengthening the twenty-first-century biomedical settings. Irrespective of ongoing technological and clinical ad- Citation: Bilal, M.; Nunes, L.V.; vancement, traditional medicinal practices to address and manage inflammatory bowel disease Duarte, M.T.S.; Ferreira, L.F.R.; (IBD) are inefficient and the effect of the administered therapeutic cues is limited. -
Osteoarthritis Treatment: an In-Depth Review of Conventional and Nonconventional Interventions for Symptomatic Relief and Novel Disease Modifying Modalities
PSM Biological Research 2017 │Volume 2│Issue 3│97-110 ISSN: 2517-9586 (Online) www.psmpublishers.org Review Article Open Access Osteoarthritis Treatment: An In-depth Review of Conventional and Nonconventional Interventions for Symptomatic Relief and Novel Disease Modifying Modalities Mubashar Rehman1*, Asadullah Madni1, Saima Khalil2, Muhammad Umair3, Tauseef Nasir4, Omer Saeed5, Muhammad Naeem Iqbal6,7 1Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan. 2Moon Clinic and Nishtar Paramedical College, Toba Tek Singh 36050, Pakistan. 3Department of Pharmacology, University of Veterinary and Animal Sciences, Lahore 54000, Pakistan. 4Retail Pharmacy, Shifa International Hospital, Faisalabad 38000, Pakistan. 5Retail Pharmacy, Shifa International Hospital, Gujranwala 52250, Pakistan 6The School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, China. 7Pakistan Science Mission (PSM), Noor Kot 51770, Pakistan. Received: 22.Mar.2017; Accepted: 10.June.2017; Published Online: 06.Aug.2017 *Corresponding author: Mubashar Rehman; Email: [email protected] Abstract Osteoarthritis (OA) is characterized by degradation of joint cartilage which produces severe pain and swelling leading to immobility of the joint. OA can affect people of all age, gender and geographical locations, and the cost associated with long term medication, hospitalization and the loss of daily work hours stigmatizes the patient’s life. Conventionally, the treatment of OA is done with analgesic to relieve pain, but due to notorious side effects profile of NSAIDs and corticosteroids, dependence phenomenon with opioids and continuous underlying degradation of joint, the analgesics cannot be relied upon as sole therapeutic agent. Physical therapies, exercise, modification of lifestyle and use of supportive devices have shown effectiveness in prevention and treatment of mild OA. -
Supplements for the Treatment of Osteoarthritis
Supplements for the Treatment of Osteoarthritis What is osteoarthritis? Osteoarthritis (OA), the most common form of joint disease, a “wear and tear” disorder. It results from the degeneration of the articular cartilage lining the joints. Normally, cartilage reduces the amount of friction caused by bones rubbing against each other and acts as a shock absorber to protect bones during everyday use. OA causes thinning and ultimate loss of cartilage. Therefore the structure and function of the joint changes, causing pain, swelling, stiffness, or limited movement. This can affect any joint, but most commonly affects the hips, knees, and hands. Which supplements can help treat OA, and how might they work? Glucosamine, chondroitin sulfate, and SAM-e (s-adenosylmethionine) are supplements that have gained a great deal of attention due to their possible role in relieving symptoms of OA with minimal side effects. These supplements are thought to work by the following mechanisms but this has not yet been proven. Glucosamine is a natural substance often derived from crab, lobster, or shrimp shells. The theory is that it provides the building blocks needed to support growth, repair, and maintenance of cartilage within joints. Glucosamine may prevent or slow the progression of OA by helping to rebuild the damaged cartilage. It may also have a possible anti-inflammatory (decreases swelling) effect on arthritic joints. Chondroitin sulfate is found naturally in cartilage. It is believed to protect articular cartilage from enzymes that destroy cartilage. It may also help to prevent the formation of microscopic blood clots. This leads to improvement in the blood supply to joint tissues.